IMA has submitted its response to the ESMA consultation on EMIR TS. It warns about the "repapering" that compliance with EMIR will involve. Additionally, it notes the need to support the introduction of an agency model for clearing OTC derivatives. (Source: IMA Response to ESMA Consultation on EMIR TS)